DERM Dermira, Inc.

33.84
+0.6  (1.81%)
Previous Close 33.24
Open 33.08
Price To book 4.71
Market Cap 1.20B
Shares 35,603,000
Volume 216,975
Short Ratio 7.16
Av. Daily Volume 220,582

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data from first trial released October 2016 - endpoints met. Second trial data released December 8, 2016 - endpoints met. Data from third and final trial met primary endpoint - January 19, 2017. FDA filing due 3Q 2017.
Cimzia
Moderate-to-severe plaque psoriasis
Phase 3 trial initiation announced January 3, 2017. Data are due 1H 2018.
Olumacostat glasaretil (DRM01)
Acne
Phase 3 data released June 2016. NDA Filing 2H 2017.
DRM04
Primary axillary hyperhidrosis

Latest News

  1. Dermira to Present at Leerink Partners 6th Annual Global Healthcare Conference
  2. Dermira Psoriasis Drug Cimzia Did Well In Study
  3. Final CIMZIA® (certolizumab pegol) Phase 3 Trial Meets Primary Efficacy Endpoint in Patients with Moderate-to-Severe Chronic Plaque Psoriasis
  4. Dermira Provides Corporate Update
  5. Dermira Provides Corporate Update
  6. Dermira, Inc. breached its 50 day moving average in a Bullish Manner : DERM-US : January 5, 2017
  7. Lori Lyons-Williams Joins Dermira as Chief Commercial Officer
  8. Lori Lyons-Williams Joins Dermira as Chief Commercial Officer
  9. Dermira Elects Emmanuel Caeymaex to Board of Directors
  10. DERMIRA, INC. Files SEC form 8-K/A, Change in Directors or Principal Officers
  11. Dermira Elects Emmanuel Caeymaex to Board of Directors
  12. Dermira Initiates Phase 3 Clinical Program in Acne
  13. Dermira Initiates Phase 3 Clinical Program in Acne
  14. ETFs with exposure to Dermira, Inc. : December 29, 2016
  15. DERMIRA, INC. Files SEC form 8-K, Change in Directors or Principal Officers
  16. ETFs with exposure to Dermira, Inc. : December 9, 2016
  17. Dermira, Inc. :DERM-US: Earnings Analysis: Q3, 2016 By the Numbers : December 8, 2016
  18. Second CIMZIA® (certolizumab pegol) Phase 3 Trial Meets Co-primary Efficacy Endpoints in Patients with Moderate-to-Severe Chronic Plaque Psoriasis
  19. Is Merit Medical Systems, Inc. (MMSI) A Good Stock To Buy?
  20. Is Bottomline Technologies (EPAY) A Good Stock To Buy?